Atrial Fibrillation Recurrence in Sleep Apnea - Full Text View

Purpose

This randomized, controlled trial is designed to test whether treatment of sleep disordered breathing (SDB) with positive airway pressure (PAP) therapy alters the natural history of atrial fibrillation (AF). Patients with recent AF who are now in sinus rhythm, and found to have SDB (obstructive and/or central sleep apnea) by formal sleep study but without complaints of daytime sleepiness, are randomized to PAP therapy to eradicate SDB or to usual care (medical management as prescribed by the patient's cardiologist).

Condition	Intervention
Sleep Apnea Atrial Fibrillation	Device: Adaptive Servo-Ventilation Other: Usual Care


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
Official Title:	A Randomized Trial of Positive Airway Pressure Therapy In Atrial Fibrillation Recurrence In Sleep Apnea

Resource links provided by NLM:

Genetics Home Reference related topics: familial atrial fibrillation

MedlinePlus related topics: Atrial Fibrillation Sleep Apnea

U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:

Number of Subjects Who Had Atrial Fibrillation Recurrence at 1 Year [ Time Frame: 1 year ]

Secondary Outcome Measures:

Mean Score on Epworth Sleepiness Scale (ESS) at Baseline and 12 Month Visit [ Time Frame: baseline, 12 months ]
The ESS is a measure of general level of sleepiness. The ESS asks subjects to rate their usual chances of dozing off or falling asleep in 8 different situations or activities that most people engage in as part of their daily live, although not necessarily every day. The questionnaire has 8 questions, with responses ranging from 0 (would never dose) to 3 (high chance of dozing). Therefore the total score could range from 0 (no sleepiness) to 24 (high chance of dozing).
Mean Score on Functional Outcomes of Sleep Questionnaire (FOSQ) [ Time Frame: baseline, 12 months ]
The FOSQ is a disease-specific quality of life questionnaire to determine functional status in adults. The measures are designed to assess the impact of disorders of excessive sleepiness on multiple activities of everyday living. There are 30 items on the questionnaire consisting of 5 factor subscales. The subject rates the difficulty of performing a given activity on a 4-point scale (no difficulty to extreme difficulty). A higher score indicates greater difficulty or impact of sleepiness on daily living. FOSQ total score ranges from 0 (no difficulty) to 120 (extreme difficulty).


Enrollment:	25
Study Start Date:	October 2009
Study Completion Date:	May 2012
Primary Completion Date:	May 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Therapeutic Positive Airway Pressure Subjects randomized to this arm received nightly Adaptive Servo-Ventilation during sleep for 12 months.	Device: Adaptive Servo-Ventilation Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
Usual Care Subjects randomized to this arm received medical management for 12 months as prescribed by their cardiologist.	Other: Usual Care Subjects randomized to this arm received medical management as prescribed by their cardiologist.

Detailed Description:

Sleep apnea is a common disorder which is increasingly implicated in the pathogenesis of cardiovascular disease. Observational data suggest that sleep apnea may play a role in the development of atrial fibrillation (AF), and may even predispose to recurrence of AF following electrical cardioversion (DCCV). Because of biases and confounders inherent to observational studies, we propose a randomized clinical trial to assess the effects of treatment of sleep apnea in subjects with AF treated with DCCV. Following polysomnography, subjects with sleep apnea will be randomized to positive airway pressure (PAP) or usual medical care and followed for up to one year to compare a primary outcome of AF recurrence rate.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Age >18 yrs
Successful electrical or chemical cardioversion within previous 2 weeks
Greater than 2 episodes symptomatic AF in previous 6 months

Exclusion criteria:

Currently on PAP therapy
Moderate to severe pulmonary disease
Neurologic impairment (h/o cerebrovascular accident (CVA), transient ischemic attack (TIA), neuromuscular disease, diaphragmatic paralysis)
Severe cardiac disease (LVEF<40%, greater than mild to moderate valvular disease)
Post cardiac surgery AF
Congenital heart disease
Renal disease (Scr > 2.5)
Excessive ethanol (EtOH) use (>2 drinks/day)
Anatomically fixed nasal obstruction (severe septal deviation, uncontrolled rhinitis)
History of motor vehicle or occupational accident related to sleepiness.
Epworth Sleepiness Scale score >18 (out of maximum score of 24).

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00263757

Locations


United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905

Sponsors and Collaborators

Mayo Clinic

National Heart, Lung, and Blood Institute (NHLBI)

National Center for Research Resources (NCRR)

ResMed Foundation

Investigators


Principal Investigator:	Sean M. Caples, D.O.	Mayo Clinic

More Information


Responsible Party:	Sean M. Caples, D.O, Mayo Clinic
ClinicalTrials.gov Identifier:	NCT00263757 History of Changes
Other Study ID Numbers:	1254-05 1RC1HL099534 ( U.S. NIH Grant/Contract ) UL1RR024150 ( U.S. NIH Grant/Contract )
Study First Received:	December 7, 2005
Results First Received:	May 30, 2014
Last Updated:	July 7, 2014

Additional relevant MeSH terms:


Atrial Fibrillation Apnea Sleep Apnea Syndromes Recurrence Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Respiration Disorders	Respiratory Tract Diseases Signs and Symptoms, Respiratory Signs and Symptoms Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases Disease Attributes

ClinicalTrials.gov processed this record on September 21, 2017